From Discovery to Development
The articles in this eBook examine key trends driving this transformation, from AI-enabled discovery and experimental validation to advanced cell, gene, and biologic platforms, and explore how the next generation of therapies will move from concept to clinic. The post From Discovery to Development appeared first on GEN - Genetic Engineering and Biotechnology News .
The life sciences industry is undergoing a significant transformation as various therapeutic modalities converge to redefine drug development. Artificial intelligence, cell and gene therapies, antibody engineering, mRNA platforms, viral vectors, antibody-drug conjugates, and multispecific antibodies are all playing a crucial role in reshaping the landscape.
This convergence is enabling developers to access a growing toolkit of advanced therapeutic technologies, each with unique advantages and challenges. As a result, the traditional drug development framework is evolving rapidly, with developers now needing to consider developability, manufacturability, analytical characterization, and clinical strategy much earlier in the process.
The future of drug development lies in effectively integrating these technologies, with organizations that combine discovery expertise, modality-specific knowledge, CMC capabilities, and manufacturing execution being best positioned to navigate this complex environment.
Brief written by urgent.news from GEN Biotechnology's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
